Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
135
resultados
Última actualización
01/09/2024 [07:12:00]
Resultados 50 a 75 de 135
Resumen de: WO2024118630A2
Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or post-operative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.
Resumen de: WO2024118521A2
Described herein are systems and methods for identifying gene clusters in patients that have Crohn's Disease (CD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: US2024183867A1
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
Resumen de: EP4378536A2
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
Resumen de: CA3224278A1
A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.
Resumen de: CA3219846A1
The present disclosure is generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Resumen de: MX2024000466A
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ? 0.07 as determined by their raw p-value or an average discriminatory p-value of ? 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.
Resumen de: US2024174984A1
Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.
Resumen de: US2024173365A1
The disclosure relates to methods for colonizing a microbiome, by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing inflammatory bowel disease, methods for reducing the risk of inflammatory bowel disease and/or reducing the occurrence of inflammatory bowel disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing graft versus host disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject.
Resumen de: US2024174758A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD). and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: CA3224278A1
A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.
Resumen de: CN118064569A
The invention particularly relates to a novel diagnosis and treatment marker for an inflammatory bowel disease (IBD) and application of the novel diagnosis and treatment marker, and more particularly relates to application of CD36 in diagnosis and treatment of the IBD. According to the invention, bioinformatics analysis and exploration are utilized to confirm that colon CD36 has good correlation with IBD in crowds, and animal models are also verified, so that a new diagnosis and treatment marker is provided for clinical diagnosis and treatment of IBD, and the application has important clinical significance.
Resumen de: EP4372003A1
The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1α (REGIA), each antibody in the antibody combination can specifically bind to REG1A with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REG1A. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REG1A-related diseases.
Resumen de: JP2024069231A
To provide a method of treating a patient suffering from Inflammatory Bowel Disease (IBD).SOLUTION: The method comprises the steps of: a) measuring the concentration of vedolizumab in a patient, where an induction phase dosing regimen of vedolizumab was administered to the patient at least two weeks before; b) selecting the patient whose measurement of vedolizumab in step a) indicates low clearance; and c) administering vedolizumab to the selected patient, thereby treating IBD.SELECTED DRAWING: None
Resumen de: CN118050517A
The invention discloses an application of a human serum biochemical index combination in preparation of a product for screening or auxiliary diagnosis of an inflammatory bowel disease, the inflammatory bowel disease IBD comprises Crohn's disease CD and ulcerative colitis UC, the product for screening or auxiliary diagnosis of the IBD takes a human serum sample as a sample to be detected, and the levels of TP, ALB, PA, GLOB, GGT, LDH and DBIL in the sample to be detected are detected, (1) the combination of TP, ALB and PA is used for detecting the level of TP, ALB, PA, GLOB, GGT, LDH and DBIL in the sample to be detected, and (2) the combination of TP, ALB and PA is used for detecting the level of DBIL in the sample to be detected; the kit is used for screening IBD patients and normal people; (2) a PA + LDH combination for screening CD patients and normal people; (3) a combination of ALB and PA for screening UC patients and normal people; and (4) the combination of GLOB, GGT, LDH and DBIL is used for auxiliary diagnosis of UC patients and CD patients.
Resumen de: CN118050521A
The invention discloses an excrement metabolism marker combination for early diagnosis or screening of Crohn's disease and application. The fecal metabolism marker combination is a combination of at least any five of tetradecyl phosphonic acid, 4-acetaminobutyric acid, LPE (0: 0/18: 2), LPE (18: 2/0: 0), methylmalonic acid, 4-oxovaleric acid, 4-hydroxyisoquine guanidine, N-(p-toluoyl) glycine, L-homoarginine, N-palmitoyl glycine, formyl tetrahydrofolic acid and folinic acid. The fecal metabolism marker provided by the invention can accurately perform early diagnosis or screening of Crohn's disease, is high in sensitivity, can replace an existing early diagnosis or screening method of Crohn's disease based on blood and fecal detection, reduces the missed diagnosis rate, reduces the detection cost, and has clinical use and popularization values.
Resumen de: CN118045038A
The invention belongs to the field of biomedical materials, and discloses a three-enzyme active nano-enzyme oral liquid for integrated diagnosis and treatment of inflammatory bowel diseases. The main component of the oral liquid is a nano-enzyme with activity similar to catalase (CAT), superoxide dismutase (SOD) and hydroxyl scavenging enzyme (OHS), and the oral liquid can remove reactive oxygen species (ROS) at inflammation, is stable and non-toxic in gastrointestinal tracts, can specifically target diseased colon and relieve oxidative stress, can also be applied to computed tomography (CT) imaging, and can be applied to the field of medical science and medical science. Enteritis can be quickly diagnosed. Compared with 5-aminosalicylic acid clinically used for treating inflammatory enteritis, the 5-aminosalicylic acid has better treatment effect and lower manufacturing cost.
Resumen de: US2024159772A1
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: US2024159763A1
The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e g inflammatory bowel disease, in felines.
Resumen de: WO2024102901A1
The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R3 and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
Resumen de: US2024158485A1
The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Resumen de: JP2024065767A
To provide detection methods for irritable bowel syndrome using enteric bacteria.SOLUTION: Detection methods for irritable bowel syndrome include detecting at least one bacteria selected from the group consisting of bacteria belonging to the genus Lachnospiraceae Blautia, bacteria belonging to the genus Ruminococcaceae Oscillospira, and Faecalibacterium prausnitzii species in a subject's fecal matter.SELECTED DRAWING: Figure 2
Resumen de: CN118039136A
The invention discloses a colitis diagnosis system and device and a storage medium. The system comprises an endoscope, a differential diagnosis device and an output device, and the endoscope is used for generating an intestinal tract internal image corresponding to a patient and sending the intestinal tract internal image to the differential diagnosis device; the output equipment is used for receiving the diagnosis information sent by the differential diagnosis equipment and outputting the diagnosis information, and the diagnosis information is used for indicating whether the patient suffers from ulcerative colitis or ulcerative colitis combined with cytomegalovirus colitis or not. And the differential diagnosis equipment is used for generating diagnosis information according to the internal image of the intestinal tract and the test index information corresponding to the blood test of the patient.
Resumen de: CN118043071A
The present disclosure relates generally to methods of treating and diagnosing ulcerative colitis. The methods are particularly useful for treating and diagnosing specific subgroups of ulcerative colitis patients. The method is also particularly suitable for treating and diagnosing intestinal urgency in patients suffering from ulcerative colitis or suspected of suffering from ulcerative colitis. The method is also particularly suitable for treating and diagnosing frequent defecation and gut urgency in patients suffering from ulcerative colitis or suspected of suffering from ulcerative colitis.
Nº publicación: WO2024096121A1 10/05/2024
Solicitante:
BIO PALETTE CO LTD [JP]
\u682A\u5F0F\u4F1A\u793E\u30D0\u30A4\u30AA\u30D1\u30EC\u30C3\u30C8
Resumen de: WO2024096121A1
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene group, a pilus-associated gene group, and a two-component regulatory system gene group has been modified. The modification suppresses inflammation in a host compared to microorganisms in which the gene is unmodified.
BOPI
Sede Electrónica
